On Jun 29, 2018 Ziopharm Oncology Inc (NASDAQ:ZIOP) Sellers Increased Their Shorts By 0.09%

June 29, 2018 - By Sarah Holford

It was showed an increase on Ziopharm Oncology Inc (NASDAQ:ZIOP)’s shares shorted with 0.09%. In June was announced ZIOP’s total 35.65M shares shorted by FINRA. The up change of 0.09% from 35.62M shares was reported. Previous ZIOP’s position will need 48 days to recover. It has 751,200 average volume. Ziopharm Oncology Inc float short is 32.78%.

The stock decreased 1.95% or $0.06 during the last trading session, touching $3.01.Currently ZIOPHARM Oncology, Inc. is downtrending after 31.35% change in last June 29, 2017. ZIOP has also 572,478 shares volume. ZIOP underperformed the S&P 500 by 43.92%.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The firm is valued at $424.01 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .Currently it has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Total analysts of 2 have positions in Ziopharm Oncology (NASDAQ:ZIOP) as follows: 1 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 50%. Since March 5, 2018 according to StockzIntelligence Inc Ziopharm Oncology has 3 analyst reports. On Monday, May 14 the firm has “Buy” rating given by H.C. Wainwright. The stock rating was maintained by H.C. Wainwright with “Buy” on Monday, March 5. On Monday, June 18 the rating was downgraded by JP Morgan to “Underweight”.

For more ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news posted briefly go to: Nasdaq.com, Globenewswire.com, Streetinsider.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide” posted on June 18, 2018, “Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19 …” on June 18, 2018, “Pre-Open Movers 06/18: (PTCT) (CBPO) (RCII) Higher; (CBIO) (ZIOP) (RDFN) Lower (more…)” with a publish date: June 18, 2018, “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” and the last “Ziopharm down 12% premarket on likely delay in Phase 1 CAR-T study” with publication date: June 18, 2018.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.